GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nomelcitinib   Click here for help

GtoPdb Ligand ID: 14360

Synonyms: compound 52 [WO2022135430] | D-2570
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Nomelcitinib (WHO proposed list 134; Feb 2026) is the INN for a Janus kinase inhibitor, that is intended for use as a anti-inflammatory/immunosuppressant agent. The chemical structure is claimed in patent WO2022135430A1 (InventisBio) [1]. This may be the INN for their lead orally bioavailable tyrosine kinase 2 (TYK2) JH2 pseudokinase inhibitor D-2570.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 149.83
Molecular weight 424.86
XLogP 1.45
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C([2H])([2H])([2H])NC(=O)C1=C(C=C(NC(=O)C2CC2)N=N1)NC3=NC=C(C=C3S(=O)(=O)C)Cl
Isomeric SMILES [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=C(C=C(C=N2)Cl)S(=O)(=O)C)NC(=O)C3CC3
InChI InChI=1S/C16H17ClN6O4S/c1-18-16(25)13-10(6-12(22-23-13)21-15(24)8-3-4-8)20-14-11(28(2,26)27)5-9(17)7-19-14/h5-8H,3-4H2,1-2H3,(H,18,25)(H2,19,20,21,22,24)/i1D3
InChI Key QZZGWCBTIULDRA-FIBGUPNXSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
D-2570 has advanced to clinical trials to determine safety and efficacy in the treatment of autoimmune diseases, principally psoriasis [2-3], plus ulcerative colitis and systemic lupus erythematosus.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07326813 A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis. Phase 3 Interventional InventisBio Co., Ltd
NCT07311200 A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) Phase 2 Interventional InventisBio Co., Ltd
NCT07035041 A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis Phase 2 Interventional InventisBio Co., Ltd
NCT07130604 Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis Phase 3 Interventional InventisBio Co., Ltd